文献速递临床试验与 GCP医学教育与科研方法

癌症临床试验中的患者沟通与体验:专科临床试验中心的混合方法研究

Patient communication and experiences in cancer clinical drug trials: a mixed-method study at a specialist clinical trials unit.
PubMed 文献 · Trials · 2023-06-13

该混合方法研究邀请在Parkville癌症临床试验中心参加药物临床试验的患者填写定制在线问卷和/或接受定性访谈,按首次试验治疗后的时间分为新入组(≥1至≤13周)、中期(≥14至≤26周)和长期(≥52周)三个队列。2021年5月至6月,210例患者完成问卷(应答率64%,60%男性),20例完成访谈(60%男性),18例两者均完成。问卷显示各试验阶段患者对试验信息提供和与试验人员沟通的满意度均高(>90%),访谈提示书面试验信息可能令人不堪重负,而与工作人员和医生的口头沟通备受重视。

要点

  • 问卷显示各试验阶段患者对试验信息提供及与试验人员沟通的满意度均高(>90%)。
  • 访谈提示书面试验信息可能令人不堪重负,与工作人员和医生的口头沟通备受重视。
  • 患者指出需密切关注的环节:清晰且充分沟通的随机化操作、可靠的副作用报告途径及试验人员及时回应、试验结束时的过渡管理。

核心结论

  • 患者对试验管理总体满意度高,但指出了需要改进沟通实践的关键节点。
  • 在癌症临床试验中建立试验人员及医生与患者之间的多种有效沟通实践,可能对患者招募、保留和满意度产生广泛积极影响。

研究设计与样本

  • 混合方法研究,邀请在Parkville癌症临床试验中心参加药物临床试验的患者填写定制在线问卷和/或接受定性访谈。
  • 患者按首次试验治疗后的时间分为三组:新入组(≥1至≤13周)、中期(≥14至≤26周)和长期(≥52周)。
  • 问卷应答采用描述性统计,访谈数据采用基于团队的方法进行主题分析,问卷与访谈数据在解释阶段整合。

主要发现

  • 2021年5月至6月,210例患者完成问卷(应答率64%,60%男性),20例完成访谈(60%男性),18例两者均完成。
  • 参与患者中长期试验患者(46%)多于新入组(29%)和中期患者(26%)。
  • 问卷数据显示各试验阶段患者对试验信息提供和与试验人员沟通的满意度均高(>90%),许多患者报告试验体验超出标准治疗。
  • 访谈数据表明书面试验信息可能令人不堪重负,而与工作人员和医生的口头沟通备受重视,尤其在长期患者的入组和副作用管理方面。
  • 患者描述了临床试验轨迹中值得密切关注的要点:清晰且充分沟通的随机化操作、可靠的副作用报告途径及试验人员的及时回应、试验结束时的过渡管理以避免被遗弃感。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As cancer therapies increase in their complexity, effective communication among patients, physicians, and research staff is critical for optimal clinical trial management. Currently, we understand little about on-trial communication practices and patient trial experiences over time. This mixed-method study explored patient experiences of participating in a clinical drug trial at different time points, focussing on patient communication with trial staff. METHODS: Patients enrolled in clinical drug trials conducted at the Parkville Cancer Clinical Trials Unit were invited to complete a tailored online survey and/or a qualitative interview. Patients were recruited to three cohorts based on time since the first trial treatment: new (≥ 1 to ≤ 13 weeks), mid- (≥ 14 to ≤ 26 weeks), and long-term (≥ 52 weeks) trial patients. Descriptive statistics were calculated for survey responses. Interview data were analysed thematically with a team-based approach. Survey and interview data were integrated at the intepretation stage. RESULTS: From May to June 2021, 210 patients completed a survey (response rate 64%, 60% male), 20 completed interviews (60% male), and 18 completed both. More long-term trial patients (46%) participated than new (29%) and mid-trial patients (26%). Survey data showed high (> 90%) patient satisfaction with the provision of trial information and communication with trial staff across trial stages, and many reported trial experiences as above and beyond standard care. Interview data indicated that written trial information could be overwhelming, and verbal communication with the staff and physicians was highly valued, especially for enrolment and side effect management among long-term patients. Patients described the key points along the clinical trial trajectory that merit close attention: clear and well-communicated randomisation practices, reliable pathways for side effect reporting and prompt response from the trial staff, and end-of-trial transition management to avoid a sense of abandonment. CONCLUSION: Patients reported high overall satisfaction with trial management but outlined key pinch points requiring improved communication practices. Establishing a range of effective communication practices among trial staff and physicians with patients in cancer clinical trials may have a wide range of positive effects on patient accrual, retention, and satisfaction.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Forbes Shepherd R, Bradford A, Lieschke M, et al. Patient communication and experiences in cancer clinical drug trials: a mixed-method study at a specialist clinical trials unit. Trials. 2023. PMID: 37312206. doi:10.1186/s13063-023-07284-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。